These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 38262966)
1. Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma. Li XQ; Yin SQ; Chen L; Tulamaiti A; Xiao SY; Zhang XL; Shi L; Miao XC; Yang Y; Xing X BMC Cancer; 2024 Jan; 24(1):116. PubMed ID: 38262966 [TBL] [Abstract][Full Text] [Related]
2. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Hu Y; Chen Y Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315 [TBL] [Abstract][Full Text] [Related]
3. Identification of m6A-related lncRNAs-based signature for predicting the prognosis of patients with skin cutaneous melanoma. Lin W; Tan ZY; Fang XC SLAS Technol; 2024 Feb; 29(1):100101. PubMed ID: 37541541 [TBL] [Abstract][Full Text] [Related]
4. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma. Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576 [TBL] [Abstract][Full Text] [Related]
5. Prognostic signature based on m6A-related lncRNAs to predict overall survival in pancreatic ductal adenocarcinoma. Wu Q; Chen L; Miao D; Jin Y; Zhu Z Sci Rep; 2022 Feb; 12(1):3079. PubMed ID: 35197523 [TBL] [Abstract][Full Text] [Related]
6. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer. Liu Y; Wang T; Fang Z; Kong J; Liu J J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer. Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183 [TBL] [Abstract][Full Text] [Related]
8. Identification of N6-Methyladenosine-Associated Long Non-coding RNAs for Immunotherapeutic Response and Prognosis in Patients With Pancreatic Cancer. Yu X; Dong P; Yan Y; Liu F; Wang H; Lv Y; Song M; Yao Q; Hu S Front Cell Dev Biol; 2021; 9():748442. PubMed ID: 34621754 [TBL] [Abstract][Full Text] [Related]
9. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer. Song Y; Qu H BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619 [TBL] [Abstract][Full Text] [Related]
10. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma. Zhao J; Lin X; Zhuang J; He F Front Genet; 2021; 12():714697. PubMed ID: 34777460 [No Abstract] [Full Text] [Related]
11. Prognostic Value of Drug Targets Predicted Using Deep Bioinformatic Analysis of m6A-Associated lncRNA-Based Pancreatic Cancer Model Characteristics and Its Tumour Microenvironment. Cao PW; Liu L; Li ZH; Cao F; Liu FB Front Genet; 2022; 13():853471. PubMed ID: 35547245 [TBL] [Abstract][Full Text] [Related]
12. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients. Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697 [TBL] [Abstract][Full Text] [Related]
13. M6A-Related Long Non-Coding RNA Displays Utility in Predicting Prognosis, Portraying the Tumor Immune Microenvironment and Guiding Immunotherapy in Pancreatic Ductal Adenocarcinoma. Xu G; Ji Y; Wang L; Xu H; Shen C; Ye H; Yang X Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992083 [TBL] [Abstract][Full Text] [Related]
14. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis. Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550 [TBL] [Abstract][Full Text] [Related]
15. Identification of m6A-Related lncRNAs Associated With Prognoses and Immune Responses in Acute Myeloid Leukemia. Li D; Liang J; Cheng C; Guo W; Li S; Song W; Song Z; Bai Y; Zhang Y; Wu X; Zhang W Front Cell Dev Biol; 2021; 9():770451. PubMed ID: 34869365 [No Abstract] [Full Text] [Related]
16. Comprehensive analysis of m6A modification patterns and m6A-related lncRNAs as potential biomarkers in lung adenocarcinoma. Wang S; Gu X; Xu D; Liu B; Qin K; Yuan X Environ Toxicol; 2024 Apr; 39(4):2285-2303. PubMed ID: 38148718 [TBL] [Abstract][Full Text] [Related]
17. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma. Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168 [No Abstract] [Full Text] [Related]
18. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Li L; Xie R; Lu G Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555 [TBL] [Abstract][Full Text] [Related]
19. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma. Wang S; Bai H; Fei S; Miao B Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914 [TBL] [Abstract][Full Text] [Related]
20. Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs. Zhang L; Tang X; Wan J; Zhang X; Zheng T; Lin Z; Liu T Front Mol Biosci; 2021; 8():715764. PubMed ID: 34733885 [No Abstract] [Full Text] [Related] [Next] [New Search]